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Abstract
Plaque psoriasis is an autoimmune disease of the immune system affecting many adults
worldwide. Due to the inflammatory nature of the disease, adults with psoriasis are at higher risk
for thromboembolic events including heart attack and stroke. Treatment options are offered
based on the severity of disease and may have implications for reducing cardiovascular disease.
Selecting a clinically validated tool to measure the performance of a treatment or therapy has
implications for research and clinical practice and therefore it is important to understand the
strengths, weaknesses, and limitations of measures used to describe the severity of illness in
patients affected by psoriasis. Systematic reviews are research reviews that combine the evidence
of multiple studies related to a specific clinical problem to inform clinical practice (Whittemore
& Knafl, 2005). This systematic review of the literature examined the clinically validated tools
used in large randomized controlled trials within the past ten years. The results of this study
found that authors of major studies evaluating the effectiveness of treatment on adults with
psoriasis used a combination of clinically validated tools to determine the severity of disease.
The instruments chosen include the Psoriasis Area and Severity Index (PASI), the Static
Physicians Global Assessment (sPGA), and Body Surface Area (BSA).
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A Comparison of Measures to Determine the Severity of Disease in Adults with
Psoriasis: A Systematic Review

Background/Statement of the Problem
Psoriasis is a complex autoimmune disorder with a prevalence in Europe and
North America at about 2%, according to the World Health Organization (WHO)
(Boehncke, 2015). Mild forms of the disease account for nearly 70%-80% of all cases
(Boehncke, 2015). Manifestations of the disease include plaque, accounting for 90% of
all cases, arthritic, guttate, inverse, and pustular (Boehncke, 2015). The pathogenesis of
psoriasis derives from dysregulation of the adaptive and innate immune system with
dendritic cells producing pro-inflammatory cytokines in the exacerbation stage. These
cytokines include Tissue Necrosis Factor-alpha (TNFa) and Interleukin 12, 23 and 17
(Boehncke, 2015). Successful use of inhibitors of these cytokines further supports the
belief that psoriasis is an immune-mediated disease with genetic and environmental
factors (Boehncke, 2015).
Psoriasis being an autoimmune inflammatory disease has the potential for
developing into psoriatic arthritis (PsA) a subtype of psoriasis (Elmets et al., 2019).
According to Elmets et al. (2019), PsA has an incidence rate of 30%-33% amongst adults
with psoriasis. It is an inflammatory arthritis that affects both joints, tendons, and
ligaments (Elmets et al., 2019). In fact, among patients with a 30-year history of
psoriasis, the prevalence reaches about 20.5% indicating that the longer one lives with
psoriasis, the greater the chance of developing PsA (Elmets et al., 2019). Therefore,
screening for PsA is important in the management of adults with psoriasis. Psoriatic
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arthritis may present as painful and swollen joints in the hands, feet, knees, and arm or
spine and can be challenging to differentiate between other forms of arthritis (Elmets et
al., 2019).
The importance of screening for PsA is to initiate prompt treatment and reduce
further joint damage (Elmets et al., 2019). The C-Reactive protein, a test that measures
inflammation is neither sensitive nor specific to confirm a diagnosis of PsA (Elmets et al.,
2019). Tom et al. (2015) reiterates this point and state that it’s crucial to have screening
tools that can detect the presence of PsA as early as possible. The authors report that
early treatment has the benefits of improving quality of life, reducing joint damage and
greater longevity.
A paper published as a joint venture between the American Academy of
Dermatologists (AAD) and the National Psoriasis Foundation (NPF) provides guidance in
clinical decision making in the management of psoriatic disease (Elmets et al., 2019).
Using an evidence-based model, the authors searched the literature to find critical clinical
questions related to comorbidities associated with psoriasis (Elmets et al., 2019). The
authors identified twelve comorbidities that are considered when either screening and or
managing patients with psoriasis (Elmets et al., 2019).
The severity of psoriasis places patients at greater risk for comorbid conditions
(Elmets et al., 2019). Chronic inflammatory diseases, such as psoriasis, are known risk
factors for cardiovascular disease (Elmets et al., 2019). According to Elmets et al. (2019),
the incidence of heart disease per 1000 person-years is 3.58 for the general population,
increasing to 4.04 for patients with moderate psoriasis and 5.13 for patients with severe
psoriasis. The authors also found that moderate and severe psoriasis are independent risk
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factors for stroke (Elmets et al., 2019). One method for evaluating mortality in adults
with psoriasis is the Major Adverse Cardiovascular Events (MACE), which is a
composite endpoint used by researchers (Elmets et al., 2019). MACE comprises four
events: heart failure, sudden cardiac death, myocardial infarction, and stroke falling under
one umbrella (Elmets et al., 2019). The authors determined that psoriasis accounts for an
additional 11,000 MACEs per year, underscoring the need for providers to discuss
cardiovascular risk with their patients.
Metabolic syndrome is a cluster of chronic health conditions that play a
significant role in mortality in patients with psoriasis (Elmets et al., 2019) The five
conditions are increased abdominal girth, elevated triglycerides, low HDL cholesterol, an
elevated blood pressure and high fasting blood sugar (Elmets et al., 2019). Metabolic
syndrome is diagnosed when a person has three out of the five conditions (Elmets et al.,
2019). In a comparison to practice-matched control patients, the authors reported that
34% of psoriatic patients meet the criteria for metabolic syndrome as compared to the
control group in which 26% of the patients met criteria (Elmets et al., 2019). The authors
also reported across the board, psoriasis patients scored higher for each individual
component of metabolic syndrome as compared to control groups; obesity (385 versus
31%), elevated triglycerides (36% versus 28%), hypertension (31%versus 28%) and
elevated glucose (22% versus 16%) (Elmets et al., 2019). The significance of these
findings is that the prevalence of metabolic syndrome is higher in patients with psoriatic
disease and worsens with disease severity (Elmets et al., 2019).
Treatment options for patients include conventional treatments and biologics
(Boehncke, 2015). Conventional therapies include vitamin-D derivatives, phototherapy,
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topical corticosteroids, homeopathic and oral immunosuppressive drugs like
methotrexate, for example (Boehncke, 2015). Biologic agents are the newest available
treatments that target the disease in a fundamentally different way. They are derived
using monoclonal antibody technology and include Tissue Necrosis Factor Alpha (TNFa)
inhibitors, interleukin 12 and 23 blockers (IL 12, 23), and interleukin 17A (IL-17A)
blockers (Boehncke, 2015). Although slightly different, most guidelines do have a
threshold for transitioning from conventional therapies to biologics (Golbari et al., 2018;
Llamas-Velasco et al., 2017; Menter et al., 2019). Early screening and detection are
essential to identify patients who may be candidates for biologic therapy (Elmets et al.,
2019).
Practice guidelines for the treatment of psoriasis are evolving and will continue to
change as new treatments become available (Golbari et al., 2018). According to Menter et
al. (2019), the severity of psoriasis determines treatment. Menter et al. (2019) state that
most patients with mild to moderate forms of the disease can be managed with topical
medicine and phototherapy, whereas patients with moderate to severe forms of the
disease should be managed with biologics alone or in combination with topical or
systemic medicine. Currently there is no consensus amongst experts on how to classify
the severity of psoriasis (Golbari et al., 2018). However, the professional organizations
such as the National Psoriasis Foundation, the American Academy of Dermatology, the
European Consensus Program, the European Dermatology Forum, the British Association
of Dermatologists, and the Merit Based Incentive-Payment System (MIPS) publishing
consensus statements use one or more validated tools such as the Psoriasis Area and

5
Severity Index (PASI), Body Surface Area (BSA) and subjective questionnaires, such as
the Dermatology Life Quality Index (DLQI) (Golbari et al., 2018).
According to Golbari et al. (2018), systemic treatments must be considered for a
BSA of 5%-10%, which is considered severe disease. They conceded this approach may
be problematic because affected areas such as the palms, soles, hair, and genitals may be
difficult to treat and should be classified as severe. They also reported that if the disease
is causing psychological harm, then it should also be considered severe (Golbari et al.,
2018). Menter et al. (2019) echoed this point but defined mild psoriasis as <3% BSA,
moderate as 3% to 10% BSA and severe as greater than 10% BSA. Menter stated that the
PASI is clinically important for appraising the patient's response to treatment but is not
useful for guiding clinical practice or management of the disease (Menter et al., 2019). In
contrast, Llamas-Velasco et al. (2017) reported that the PASI is the most used scale to
measure the severity of psoriasis and drive clinical decision making. Regardless of how
the disease is measured, the authors agree that patients fall into either mild or moderate to
severe classification. The authors also agree that mild disease can be managed with
conventional therapy and moderate to severe forms should be managed with biologics.
In addition to recommendations set forth by professional organizations, it is also
necessary to consider what payers are willing to cover. Menter et al. (2019) stated that
moderate to severe forms should be treated with biologics but Golbari et al. (2018), made
a valid point that many insurance companies may require a trial of oral systemic drug
treatments and phototherapy before considering biologics. In contrast, Chi and Wang
(2014) stated the societal costs associated with not prescribing biologics, including
increased hospitalization costs, and lost productivity to name a few, offset any savings
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with less effective medicines. Biologic drugs are amongst the highest priced medications
used to treat psoriasis (Chi & Wang, 2014). The price in 2010 for the most prescribed
biologics, in US dollars ranges from a low of $13,429 for infliximab to a high of $33,574
for 90mg of ustekinumab for a 6-month supply (Chi & Wang, 2014). To evaluate the
high costs associated with biologic therapy, Chi and Wang (2014) performed a costeffective analysis by calculating the incremental cost-effectiveness ratio (ICER) to
achieve a PASI 75, a reduction in symptoms by 75%, and sPGA 0/1. The authors found
adalimumab likely to be the most cost-effective at $21,315 per PASI 75 responder, and
ustekinumab 90mg the most expensive at $1,358,900. Chi and Wang (2014) concluded
from their work that cost must be considered by clinicians and policy makers when
allocating resources.
Psoriasis is a complex, autoimmune disease that manifests as disease of the skin
and joints (Boehncke, 2015). There are many tools for evaluating the severity of disease
but there is no consensus for which tool is the best choice. Regardless of which clinical
guidelines are used, providers have the flexibility to prescribe what they feel is in the
patient’s best interest.
Therefore, the clinical question explored in this systematic review is, in adults
with psoriasis, is there a measure (or measures) of severity of the disease to guide
appropriate treatment options?
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Literature Review
Several sources were used in this literature review including: CINAHL, Academic
Search Premiere at EBSCOhost, Medline at OVID and PubMed@Tufts. Key terms
searched were psoriasis, severity of illness, and randomized controlled trial. This
literature review will examine the current literature describing clinically validated
instruments used to determine the severity of illness in adults with psoriasis.
Screening Tools for Psoriatic Arthritis
Mishra et al. (2017) compared four validated screening tools used to diagnose
psoriatic arthritis. The authors performed a noninterventional, cross-sectional analysis to
determine sensitivity and specificity of the Toronto Psoriatic Arthritis Screen 2 (ToPAS
2), the Psoriatic Arthritis Screening and Evaluation (PASE), the Psoriasis Epidemiology
Screening Tool (PEST) and the Early Arthritis for Psoriatic Patients (EARP)
questionnaires. The authors found the highest sensitivity with EARP and the highest
specificity with the ToPAS 2. These tools measure and have established specificity and
sensitivity for evaluating the presence or absence of PsA.
Use of Multiple Screening Tools
Internal consistency and reliability of instruments used to score the severity of
psoriasis has made the task of evaluating efficacy of treatments challenging. A
systematic review by Spuls et al. (2010), found that amongst the 44 available scoring
tools for determining the severity of plaque psoriasis none were clinically validated. The
authors suggested that the best tool may be a combination of tools or ones that
specifically measure a desired attribute. To validate three of the most used instruments,
Bozek and Reich (2017) performed a cross-sectional study to determine both intra-rater
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and inter-rater reliability of three tools used to measure the severity of psoriasis: the
Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Static
Physicians’ Global Assessment (sPGA). The authors observed ten practicing
dermatologists who evaluated the severity of psoriasis in nine individuals affected with
plaque psoriasis over the course of a day. Bozek and Reich (2017) used statistical
analysis to determine the inter-rater and intra-rater reliability. The authors found that the
sPGA had the highest inter-rater reliability and the BSA had the highest intra-rater
reliability. The authors found intermediate values for the PASI and concluded that there
is no one tool that is superior. Bozek and Reich (2017) suggested that the best
assessment requires several scoring tools used together, simultaneously. The authors
acknowledged the low sample size of 9 participants may be a limitation but claim that
each observer made over 50 assessments on each participant.
One Possible Solution Using the Low PASI Scoring Tool
Many researchers question the utility of the PASI tool in cases where the
involvement of disease is limited to small areas (Otero et al., 2015). To address these
concerns, Otero et al. (2015) performed a cross-sectional study to compare a new tool,
the low PASI to the original PASI and to evaluate the inter-observer reliability between
the two tools. The authors enrolled the patients who were older than 18 years, with mild
to moderate psoriasis and a total affected area of less than 10%. The authors then had two
experienced assessors evaluate each participant independently. Otero et al. (2015) used
linear mixed models to determine the inter-observer correlations between the low PASI
and PASI score. The authors found excellent inter-observer agreement amongst both
observers for each instrument. In conclusion, the authors contended that the low PASI
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scoring tool may provide more precise scoring for patients affected by psoriasis in less
than 10% of their body area. The authors stated that the utility of the classic PASI score
diminishes in areas of minimal involvement. The authors claimed the low PASI is not a
substitute for the PASI but aids in providing a better assessment when affected areas are
small.
Statistical Solution Using the Intra-Class Correlation Coefficient
Two systematic reviews (Puzenat et al., 2010; Spuls et al., 2010) that examined
the validity of severity and outcome instruments designed to measure the degree of
psoriasis failed to find one such tool. Researchers are still questioning the validity of the
most used instruments to determine the severity of psoriasis. One potential pitfall lies in
the way inter-rater agreement is derived through statistical analysis. To provide a more
realistic analysis, Gourraud et al. (2012) performed a simulation study by two
practitioners, based on an ongoing multicenter French study with 105 participants
affected by moderate to severe psoriasis who were eligible for systemic or biologic
therapy. The authors simulated a mixture of exponentially decreasing and normal
distributions of PASI scores to obtain 100 PASI scores sampled randomly out of 1000.
Gourraud et al. (2012) took this approach because they felt the normal distribution of
PASI scores is inherently skewed to the right and to overcome this limitation needs to be
analyzed as a normal distribution. The authors found that the intra-class correlation
coefficient (ICC) is preferable to other statistical methods for assessing inter-rater
agreement when normal distributions do not exist, such as in the case of PASI.
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PASI in clinical Practice
For randomized controlled trials (RCT), some experts suggest that PASI 90 (a
90% improvement in symptoms) should be used as an endpoint instead of the current
PASI 75 (a 75% improvement in symptoms) (Norlin et al., 2020). In the clinical setting, a
PASI 90 may not be a realistic goal because many individuals affected with psoriasis are
transitioning from one treatment to another. To further explore this cause for concern,
Norlin et al. (2020) performed a regression analysis to determine which factors are linked
to achieving higher PASI scores in a clinical setting. A secondary aim was to look at
health related quality of life (HRQoL) measures such as the dermatology life quality
index (DLQI) and to find associations between improved quality of life and higher
scores. The authors found that the absolute PASI score before switching to a biologic was
associated with a higher PASI percentage after the switch. The authors reported that in
clinical practice, there is no washout period as there is in randomized control studies and
therefore no baseline for comparison as treatments are modified, added to, or switched.
For this reason, Norlin et al. (2020) argued that PASI 90 is not a realistic goal in clinical
practice.
Lack of Consensus Amongst Experts
There are many tools for evaluating the severity and outcomes for adults newly
diagnosed with psoriasis, but there is no consensus about which instrument is the best
choice (Golbari et al., 2018; Llamas-Velasco et al., 2017; Menter et al., 2019). The
Psoriasis Area and Severity Index (PASI) is considered the gold standard and is used
widely amongst researchers as a primary endpoint alone or in conjunction with other
tools to measure the effectiveness of medications. Examples of studies using PASI
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include a study by Busard et al., (2017) entitled, “Optimizing adalimumab treatment in
psoriasis with concomitant methotrexate (OPTIMAP)”, and a study by Thaci et al.,
(2015) entitled, “Secukinumab is Superior to Ustekinumab in Clearing Skin of Subjects
with Moderate to Severe Plaque Psoriasis: (CLEAR)”.
Summary
Gaps exist in the literature for describing clinically validated instruments used for
evaluating the severity of psoriasis. This systematic review addressed the gap by
examining and synthesizing the findings of randomized controlled trials that are used to
measure the severity of disease in adults with psoriasis.
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Theoretical Framework
Theory of Unpleasant Symptoms
The Theory of Unpleasant Symptoms (TOUS) developed by Lenz et al. (1995)
grew naturally from students working together describing the phenomena of unpleasant
symptoms. The underpinnings of TOUS constructs describe the concepts of physiologic,
psychologic, and situational factors that affect symptoms in duration, intensity, quality,
and distress. Patients' symptoms affect performance in the areas of functional status,
cognitive functioning, or physical performance. In essence, patients' symptoms often
occur in combination with other signs and or stressors; for example, pain and fatigue may
be made worse by financial or family issues (Lenz et al., 1995).
This middle-range theory frames the clinical context of psoriatic disease by
understanding the relationship between unpleasant symptoms and quality of life.
Individuals affected by psoriasis may experience disfigurement, chronic pain, itching and
alterations in body image (Boehncke, 2015). It is important for providers to appreciate
the extent to which the disease plays a role in interfering with quality of life and selfesteem. Having a model such as TOUS assists in understanding the relationship between
the effects of disease severity and quality of life.
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Method
Purpose
This systematic review of the literature compares and synthesizes research that
examines measures used to determine the severity of disease in adults with psoriasis.
Systematic reviews and Meta-Analyses offer the highest level of evidence to inform
clinical practice and support evidence-based practice. Selecting a clinically validated tool
to measure the performance of a treatment or therapy has implications for research and
clinical practice and therefore it is important to understand the strengths, weaknesses and
limitations of measures used to describe the severity of illness in patients affected by
psoriasis.
Inclusion/Exclusion Criteria
This systematic review compared and synthesized data from randomized
controlled studies to evaluate tools used to determine the severity of disease in adults
with plaque psoriasis found in peer review journals published from 2010 until 2022
unless groundbreaking or foundational.
Exclusion criteria include non-English papers, non-randomized control trials, and
articles published earlier than 2010.
Search Strategy
The following databases were searched for published articles: CINAHL,
Academic Search Premiere at EBSCOhost, Medline at OVID and PubMed@Tufts.
References from retrieved articles using an ancestry approach were used to search the
literature. Key search terms include psoriasis, randomized controlled trials, and severity
of illness. Results were further refined by limiting studies to the past 10 years, for all
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adults, and published in scholarly, peer reviewed journals. Duplicate and unretrievable
articles were excluded. Phase one retrieval excluded all studies that were not randomized
controlled trials. In Phase two, studies were excluded if they were not a primary source,
or if the primary endpoint of the study was measuring something other than response to
treatment, such as a drug concentration measurement, tolerability of a drug, safety of a
drug, or immunogenicity of a drug. Studies were also excluded if they were not blinded,
if the study only examined mild forms of plaque psoriasis and excluded moderate or
severe forms of plaque psoriasis, or if the measures were to evaluate relationships
between two or more variants of psoriasis. Although there are many types of psoriasis,
the focus of this systematic review is plaque psoriasis, accounting for over 90% of
psoriasis cases (Boehncke, 2015). Search results were systematically recorded using
Endnote 20 for clarity and reproducibility.
Data Collection and Synthesis
Data were extracted and entered manually into an evidence summary table
(Appendix A) created in excel to appraise, analyze, and compare studies. Essential
information extracted included - study title, authors, purpose, theory, type, design,
variables, population, sampling, data collection, measurements, reliability, analysis,
significance, limitations, transferability, level of evidence, and relevance to nursing.
Critical Appraisal Tools
The Critical Appraisal Skills Programme (CASP) (Appendix C) (Critical
Appraisal Skills Programme UK, n.d. ) was used to evaluate the quality of evidence
supporting the use of diagnostic instruments designed to rate the severity of psoriasis.
The CASP appraisal tool is an accepted method for assessing the strengths and
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weaknesses of literature affecting healthcare policy or practice (Singh, 2013). A list of
discarded studies and description of why they were not selected was maintained.
Outcome Criteria
The outcome criteria were the measurable changes reported by the authors in the
RCTs selected for this systematic review.
Preferred Reporting Items for Systematic Reviews and Meta-Analysis
This systematic review used the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) as a method for study search, selection,
screening and applying inclusion and exclusion criteria. This flow diagram provided a
high-level view of records reviewed, screened, and included or excluded from the study.
Cross Analysis
Data were entered into a cross-study analysis table (Appendix D) and studies were
compared for diversity or similarities.
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Results
Figure 1
Identification of studies via databases and registers

Screening

Identification

Identification of studies via databases and registers

Records identified from*:
CINAHL (n =80)
Medline OVID (n =76)
PubMed (n = 44)
Search Premier (n =33)

Records removed before
screening:
Duplicate records removed
(n =29)

Records screened
(n =204)

Records excluded**
(n =124)

Reports sought for retrieval
(n =80)

Reports not retrieved
(n =0)

Included

Reports assessed for eligibility
(n =80)

Reports excluded:
(n =74)

Studies included in review
(n =6)

Note: Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C.,
Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R.,
Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W.,
Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021).
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The PRISMA diagram in Figure 1 represents data extracted from the following
databases: CINAHL, Medline OVID, PubMed, and Search Premier. Search criteria
included adults with psoriasis, severity of symptoms and randomized controlled trial from
2011 to 2021. The initial search yielded 233 results after removing for duplicates and
articles not available, 204 articles were included in phase one retrieval. Systematic
reviews and meta-analyses were excluded in phase two eligibility, which equaled 124
articles removed, leaving 80 for phase two eligibility. In phase two, 74 articles were
excluded if they were non-randomized, or if they were not a primary source, or if the
primary endpoint of the study was measuring something other than response to treatment,
such as a drug concentration measurement, tolerability of a drug, safety of a drug, or
immunogenicity of a drug. They were also excluded if the study was not blinded, or if the
study only examined mild forms of disease and excluded moderate or severe forms of
psoriasis or if the measures evaluated relationships between two or more variants of
psoriasis. The final number selected n=6 were double blinded randomized controlled
trials of sufficient power to measure the degree of an intervention, targeting psoriasis
vulgaris with a primary endpoint of reduction in disease severity using a method
described by the authors of each study.
The studies selected were double blinded, randomized controlled trials of adults
with plaque psoriasis with sample sizes large enough for normal distribution with enough
power to show a clinically significant improvement in symptoms. Study specific data are
found in Tables A1 through A 8 with descriptions for the purpose of the study, the
design, where the study took place, the sample size, methods, and procedures for
collecting data. Outcome data are found in Tables B1 through B8 and describe variables
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of interest, the treatment arms comparing either treatment versus placebo, treatment A
versus treatment B, or different strengths of a treatment versus placebo. Outcome criteria
also included risk difference and confidence or significance level. Tables C1 through C8
apply the critical appraisal tool to systematically appraise the evidence. The cross-study
analysis summarizes the data in a format that allows for analysis and synthesis of the
data.
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Individual Studies
Leonardi et al., (2020) (Appendix A - 1) conducted a double-blinded randomized
controlled trial designed to investigate whether risankizumab is an effective and safe
medication for reducing the severity of symptoms in adults with psoriasis. The major
points of the study were that patients treated with risankizumab versus placebo achieved
significant improvement in their symptoms at 16 weeks and with continued use as
compared to withdrawal of treatment at weeks 52 and 104. A major criticism of this study
is that it did not assess the correlation between loss of efficacy and impact on quality of
life. The design was a double-blind, randomized, placebo-controlled, two-part study
taking place in 60 sites including: Australia, Belgium, Canada, the Czech Republic,
France, Germany, Japan, South Korea, and the United States of America. The
investigators enrolled adults, older than 18 years of age with moderate to severe chronic
plaque psoriasis, for at least 6 months. The authors selected patients with a body surface
area of 10% or more, a Psoriasis Area and Severity Index of 12 or more and a Static
Physicians Global Assessment score of 3 or more. Patients were excluded if they were
not candidates for systemic or UV phototherapy. Baseline characteristics were
predominantly male of the white race, weighing less than 100 kg, mostly with moderate
psoriasis and a little over fifty percent having received previous biologic therapy. This
was a two-part study. The intervention in part A randomized patients in a 4:1 pattern to
receive risankizumab 150 mg or placebo for weeks zero to sixteen. At the end of part A
(16-28 weeks), patients unresponsive to placebo were crossed over to start risankizumab
150 mg and continued for 28-88 weeks. Patients in the initial part A treatment group, of
risankizumab 150 mg were randomized based on their sPGA score starting at week 28.
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Patients with an sPGA of 0/1 were randomized to risankizumab 150 mg or to placebo
(withdrawal of treatment). For those randomized to 150 mg at week 28, if they had an
sPGA of 3 or more by week 32, they were assigned to open label risankizumab 150 mg.
In the placebo (withdrawal group), if after 32 weeks had an sPGA of 3 or more were
assigned to open label risankizumab 150mg. The co-primary outcomes of PASI 90 and
sPGA 0/1as detailed in table B-1, shows a significant (p<0.001) improvement in PASI
and sPGA scores in patients assigned to risankizumab as compared to placebo in parts A
and B. Secondary outcomes measuring adverse events found no attributable events
directly related to risankizumab.
Lebwohl et al., (2020) (Appendix A – 2), conducted a parallel-group,
double-blind, placebo control study among adults with mild, moderate, or severe
psoriasis at risk for worsening symptoms. The researchers investigated whether
roflumilast cream, a phosphodiesterase type 4 inhibitor (PDE-4) reduces the severity of
disease as compared to placebo. The major point of this study were that a cream form of
an oral PDE-4 medication is efficacious in reducing the severity of symptoms in plaque
psoriasis. Criticisms of this study are the short duration - 12-weeks of treatment and
evaluating primary endpoints at week 6. Additionally, a small subset of patients with
intertriginous (15%) psoriasis was too small to be statistically significant. The design was
a parallel group, double blind, randomized, placebo-controlled study. The population
selected was adults 18 years or older with at least mild psoriasis indicated by an
investigators’ global assessment (IGA) score of 2 or more on a 5-point scale, a BSA of at
least 2% but not more than 20%, and a modified PASI score of 2 or more (72-point
scale). Patients were excluded if they received above average exposure to UV radiation,
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variants of psoriasis including pustular or guttate or the inability to discontinue
cytochrome p450 inducers or inhibitors. Also excluded were patients currently taking oral
PDE-4 inhibitors. Baseline characteristics were about half women and half men, mostly
of the white race, and most with moderate psoriasis on the IGA scale. The interventions
were randomized to 1:1:1, either roflumilast cream 0.3%, roflumilast cream 0.15% or
vehicle cream (placebo) and were applied once daily to affected areas for 12 weeks. The
primary outcome was an IGA score of 0 or 1 at week 6, a secondary assessment was
made for intertriginous only at baseline. Secondary outcomes were BSA and PASI scores
and patient reported Worst Itch Numeric Rating Scale (WI_NRS). Also included in the
secondary outcomes were the Psoriasis Symptom Diary score and the Dermatology Life
Quality Index. Adverse effects were monitored with investigator site assessments,
laboratory studies, 12-lead EKG, vital signs, a health, and suicide questionnaire. As seen
in Table B-2 both roflumilast cream 0.3% and 0.15% showed a clinical reduction in
symptoms at week 6 measured by an IGA score of 0 or 1 as compared to vehicle cream
with a significance level of P=0.001and P=0.004 respectively, however comparisons
could not be made between roflumilast cream 0.3% and roflumilast cream 0.15%. There
was no plan for multiple comparisons of the secondary outcomes and therefore no
conclusions were made, although the authors note the PASI scores were in the same
general direction as the primary outcome.
Papp et al., (2017) (Appendix A – 3) conducted a randomized, doubleblind randomized controlled study to answer the question, among adults with moderate to
severe plaque psoriasis, are the biosimilar drug ABP 501 and adalimumab equivalent at
reducing the severity of symptoms in psoriasis. The major findings of this study show no
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difference between ABP 501 and adalimumab in terms of efficacy or safety. A major
criticism of this study is the lead author disclosed an association with Amgen, the maker
of ABP 501 who provided funding, and participated in many aspects of the study,
including design, analysis, and approval of the manuscript. The population selected for
this study was adults 18 to 75 years old with stable moderate to severe psoriasis for at
least 6 months, who were eligible for UV photo or at least one conventional systemic
therapy. Patients were required to have a BSA of at least 10% and a PASI score of at
least 12 and a sPGA score of at least moderate on a 6-point scale. Exclusion criteria
included active tuberculosis, women of childbearing age unable to take contraception,
patients with types other than plaque psoriasis or have skin conditions that may interfere
with assessing the severity of disease. Additional criteria included no systemic therapies
within 28 days of enrollment and topical therapy limited to upper mid strength and
emollients. Baseline characteristics were mostly men in their 40s, predominantly of the
white race, with mostly moderate psoriasis on the sPGA scale. Patients were initially
randomized 1:1 to receive ABP 501 80 mg on week 1, followed by 40mg week 2 and
every 2 weeks thereafter, or adalimumab 80 mg on week 1, followed by 40 mg week 2
and every 2 weeks thereafter up to week 16. After week 16, patients in the ABP 501
group with a PASI 50 or better continued for an additional 32 weeks. Patients in the
adalimumab group with a PASI 50 or better were re-randomized in a 1:1 to ABP 501 or
adalimumab for an additional 32 weeks. As seen in Table B-3 the primary endpoint was
precent improvement in PASI from baseline, ABP 501 showed an 80.9% improvement
and adalimumab showing an 83.1% increase from baseline, statistically demonstrating
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clinical similarity. Additionally, measurements for PASI 75, 90, 100 and sPGA 0/1
demonstrated clinical similarity. Safety and adverse events were not clinically different.
Papp et al., (2018a) (Appendix B – 4) conducted a double-blind, randomized
controlled study among adults with psoriasis to see if tyrosine kinase 2 inhibition (TYK2)
drugs, such as BMS-986165 is effective at reducing the severity of symptoms in
psoriasis. The major points of this study are that elective inhibition of TYK2 is superior
to placebo in reducing the severity of symptoms. A major criticism of this study is that it
was sponsored by the drug maker, Bristol-Myers Squibb, who supplied the product and
had oversight over the design, monitoring, and analysis of the results. The trial design
was a double-blinded, placebo controlled, multinational study taking place in 82 sites in
the United States, Japan, Poland, Canada, Germany, Latvia, Mexico, and Australia. The
population selected were adults with plaque psoriasis for more than 6 months, eligible for
UV or systemic therapy, a BMI between 18 and 40 who had moderate to severe psoriasis
defined by an affected body area of more than 10%, a PASI score of 12 or more and an
sPGA score of 3 or more. Exclusion criteria were non-plaque psoriasis, other immune
disorders requiring immunosuppressive therapy, certain types of infections, such as
hepatitis B or C, tuberculosis, or previous lack of response to any agent targeting
interleukin 17 or 23. Baseline characteristics of the patients were predominantly male, in
the mid 40s, mostly of the white race with a BMI in the 20s. Patients were randomly
assigned in a 1:1:1:1:1:1 pattern of the drug BMS-986165 to either 3 mg every other day,
3 mg daily, 3 mg twice daily, 6 mg twice daily or 12 mg daily or identical looking
placebo for 12 weeks. Patients assigned to twice daily took the drug every 12 hours. The
drug was blinded to patients and investigators by using combinations of 3 mg capsules
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with placebo. The primary endpoint as seen in Table B-4 was the PASI 75 score, with
significant improvement in PASI 75 for the 3 mg daily (39% improved), 3 mg twice daily
(69% improved), 6 mg twice daily (67% improved) and 12 mg daily (75% improved).
Likewise, improvements were seen in secondary outcomes for PASI 50, 90 and 100 as
well as sPGA 0/1 and DLQI as seen in Table B-4. The authors reported more frequent
adverse events in the intervention arms as compared to placebo and reported one case of
melanoma in the 3 mg daily group.
Papp et al., (2018b) (Appendix B-5) conducted a randomized, double-blind,
placebo-controlled study among adults 18 years or older to determine if bimekizumab
(BZK) an interleukin 17a and 17f inhibitor was effective at reducing the severity of
symptoms in adults with psoriasis as compared to placebo. The major points of this study
were if interleukins 17a and 17f play a role in worsening inflammation associated with
psoriasis. Drugs, such as bimekizumab, neutralize both interleukin 17a and 17f targeting
specific steps in the inflammatory process. A major criticism of the study is the lead
author was a consultant for the biopharmaceutical company Union Chimique Belge
(UCB) who funded this research. The design was a multinational randomized, doubleblinded, placebo controlled, parallel group taking place in Canada, the Czech Republic,
Hungary, Japan, Poland, and the United States. The population consisted of adults, 18
years or older, with a diagnosis of moderate to severe plaque psoriasis, for more than 6
months defined by a PASI of 12 or more, affecting more than 10% of BSA and a sPGA
of 3 or more on a 5-point scale. Patients also needed to be eligible for UV or oral
systemic therapy. Exclusion criteria included patients who have previously taken antiinterleukin 17 therapy or who have used a biologic in the past year for psoriatic arthritis.
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Also excluded were patients with a history of a suicide attempt or suicidal thoughts
within the past 6 months or a neuropsychiatric disorder. Baseline characteristics were
mostly men, of white ethnicity, in their mid 40s, most with a history of other types of
treatments including photo, anti-TNF, other biologics and systemics. Patients were
randomized in a 1:1:1:1:1:1 pattern to receive bimekizumab every 4 weeks at doses of 64
mg, 160 mg (with 320 mg loading), 320 mg, 480 mg, or placebo. Both drug and placebo
were administered at investigational sites by unblinded study personnel since the drug
comes packaged as 160 mg/ml. As seen in Table B-5, as compared to placebo, all dosing
for BZK achieved the primary endpoint PASI 75 improvement at 61.5%, 81.4%, 85%,
93% and 83.7% respectively at week 12. Similarly, secondary endpoint achievements in
PASI 90, 100 and IGA 0/1 at 12 weeks were made as detailed in Table B-5. The
significance level for all statistical testing was set to p<0.001. Safety considerations noted
by the researchers included two patients reporting serious adverse events, one in the
placebo group developed viral meningitis and one in the treatment group developed a
large intestinal polyp and colon cancer. Other adverse effects in the treatment groups
were fungal infections (4.3% affected).
Warren et al., (2021) (Appendix A – 6) conducted a randomized, double-blind,
placebo-controlled study among adults with plaque psoriasis to evaluate the effectiveness
and safety of bimekizumab against adalimumab in plaque psoriasis. The major points of
this study were bimekizumab showed noninferiority and superiority as compared to
adalimumab in achieving PASI 90 and IGA 0/1 response but did have adverse events,
notably oral candidiasis, and diarrhea. A major criticism of this paper is that funding was
provided by UCB, the biopharmaceutical maker of bimekizumab. UCB also provided
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statistical analysis and required confidentiality agreements for the researchers. The design
was a double-blind comparison of bimekizumab and adalimumab at 77 sites across 9
countries for a 56-week period. The population was adults 18 years or older, with
moderate to severe plaque psoriasis lasting for more than 6 months. Moderate to severe
disease was defined as PASI of 12 or more, a BSA of 10% or more, and an IGA of 3 or
more on a 5-point scale. Exclusion criteria were previous exposure to either test drug and
non-responders to anti-interleukin 17 agents or any biologic agent. Baseline
characteristics were predominantly white males in their mid 40s, weighing about 90 kg,
with about 25% BSA, two thirds with moderate psoriasis and one third with severe
psoriasis. Patients were randomized 1:1:1 and assigned to either bimekizumab 320 mg
every 4 weeks to week 16, followed by bimekizumab 320 mg, every 4 weeks to week 24
and week 56, or bimekizumab 320 mg every 4 weeks to week 16 followed by
bimekizumab 320 mg every 8 weeks to weeks 24 and 56, or adalimumab 40 mg every 2
weeks, continued through weeks 16 and 24, then switched to bimekizumab 320 mg every
4 weeks until week 56. The drugs were administered subcutaneously in clinic and were
blinded to all except those staff who prepared and administered the drugs. The primary
endpoints as seen in table B-6, shows noninferiority and superiority of bimekizumab
(86.2%) over adalimumab (47.2) achieving PASI 90 and IGA score of 0/1 (85.3% and
57.2% respectively) at week 16. Secondary endpoints as seen in Table B-6 trend in the
same direction for PASI 100 at weeks 16 and 24 and PASI 75 at weeks 16 and 24. IGA
scores of 0/1 at week 24 showed the same noninferiority and superiority. There were
more adverse events including one death in the bimekizumab group, a 50-year-old man
with squamous cell carcinoma of the tongue, 6 weeks after starting bimekizumab and
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dying 5 months afterward. The authors reported oral candidiasis and diarrhea occured
more commonly in the bimekizumab group as compared to the adalimumab group.
Serious adverse events occurred in 5 patients receiving bimekizumab and 5 patients
receiving adalimumab.
Cross-Study Analysis
The cross-study analysis (Appendix D) describes the drug-drug or drug-placebo
comparisons made in each study, the primary and secondary endpoints, the validated
instruments used for evaluating the severity of psoriasis and the results of each study.
Blauvelt et al., (2020) compared risankizumab to placebo with primary outcomes of PASI
90 and sPGA 0/1, secondary outcomes were PASI 75, PAI 100, sPGA 0 and DLQI 0/1
and adverse events. Lebwohl et al., (2020) compared preparations of a PDE-4 cream
compared to vehicle cream with the primary outcome being IGA 0/1 and secondary
outcomes being IGA 0/1 plus 2-grade improvement, IGA scores at target weeks, PASI
50, 75 and 90, and WI-NRS scores.
Papp et al., (2017) compared a biosimilar drug, ABP 501against adalimumab for
efficacy and safety. The primary efficacy end point was the percent improvement in PASI
from baseline to week 16. PASI 50 and PASI 75 responses, sPGA /01. Secondary end
points were safety and monitoring for treatment-emergent adverse events (TEAEs) and
serious adverse events (SAEs), laboratory data, vital sings, and immunogenicity. Papp et
al., (2018a) compared various dosing of a TYK-2 drug against placebo. The primary end
point was a 75% or better reduction in the baseline PASI score at week 12. Secondary
end points were PASI 50, PASI 90, PASI 100 sPGA 0/1 and DLQI at 12 weeks. Papp et
al., (2018b) compared various dosing of bimekizumab to placebo. Primary efficacy end

28
point was the PASI 90 at week 12. Secondary end points were PASI 90 at week 8, PASI
75 and PASI100 at week 12 and IGA with equal or >2 categories of improvement from
baseline at weeks 8 and 12. Warren et al., (2021) compared bimekizumab to adalimumab
in a noninferiority study. The primary end points were PASI 90 at week 16 and IGA 0/1
with a 2-grade improvement from baseline at week 16. Secondary end points were PASI
100 at week 16, PASI 75 at week 4, PASI 100 at week 24 and IGA 0/1 at week 24.
Exploratory end points were DLQI score 0/1at week 25 with PASI 90 and PASI 100 and
DLQI score 0/1 at week 56 for patients switched from adalimumab to bimekizumab and
did not have a PASI 90 or DLQI 0/1 score at week 24.
All studies used a validated instrument or instruments for evaluating the severity
of psoriasis but differed in their methods. Study 1 used the PASI ≥ 12 (0 to 72) scale,
sPGA ≥ 3 (0 to 4) scale and BSA ≥ 10%. The authors noted that a PASI 75 (or 75%
improvement in symptoms) is consider clinically significant. They describe the PASI
ranging from 0 (no disease) to 72 (maximal disease) and sPGA ranging from 0 (clear) to
4 (severe). Study 2 used the IGA ≥ 2 (0 to 5) scale, Modified PASI ≥ 2 (0 to 72) scale,
WI-NRS (0 to 10) scale and Psoriasis Symptom Diary score (16 item scale) each item (0
to 10) scale The authors noted the IGA score ranges from 0 (clear), 1 (almost clear) to 4
(severe) and the modified PASI ranging from 0 (no disease) to 72 (maximal disease) The
authors described the modified PASI as a tool they developed for measuring, with
precision, areas of limited disease. Anatomical areas 1 to 9% were recorded as a fraction
rather than a whole number, allowing for derivation from all elements of the PASI score.
Study 3 used the PASI ≥ 12 (0 to 72) scale, sPGA “moderate” (0 to 6) scale and BSA
≥10%. The authors described the PASI as higher scores indicating more severe disease
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and sPGA as ranging from clear to very severe. Study 4 PASI ≥ 12 (0 to 72) scales, sPGA
moderate (0 to 5) scale and BSA ≥ 10%. The authors reported that the patient’s handprint
represents 1% of body surface area. They described the PASI as a summed score of
redness, thickness, and scaliness of psoriatic skin lesions, involving the arms, legs, trunk,
and head, ranging from 0 to 72 with higher scores indication severe disease. They
described the sPGA ranges from 0 (clear) to 5 (very severe disease). Study 5 used the
PASI ≥ 12 (0 to 72) scale, sPGA “moderate” (0 to 5) scale and BSA ≥ 10%. The authors
did not describe the clinically validated instruments however, they did define
abbreviations used: for example, the PASI 75: is a ≥75% reduction in baseline Psoriasis
Area and Severity Index. Study 6 used the PASI ≥ 12 (0 to 72) scale, IGA ≥ 3 (0 to 5)
scale and BSA≥10%. The authors stated the PASI score ranges from 0 to 72 with higher
numbers indicating severe disease. They stated the IGA ranges from 0 (clear) to 4 (severe
disease).
Blauvelt et al., (2020) concluded in their study Part A (73.2%) treatment arm
versus (2.0%) placebo achieved PASI 90 Part B treatment arm intention to treat analysis
(74% & 83.8%) achieved PASAI 90 and sPGA 0/1 at week 16 versus placebo at (2% &
6.1%). Lebwohl et al., (2020) concluded in their study 28% of the roflumilast 0.3% group
showed an improvement, 23% of the roflumilast 0.15% group showed an improvement
and 8% of the vehicle cream group showed an improvement. Papp et al., (2017)
concluded in their study the percent improvement from baseline at week 16 was 83.06%
for adalimumab and 80.91% for ABP 501. Papp et al., (2018a) concluded in their study
the largest dose of BMS-986165, 12mg daily showed a PASI 75 improvement in 75 % of
patients. Papp et al., (2018b) concluded in their study there was significant (p=<0.001)
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PASI 75, 90, 100 and IGA improvement in all bimekizumab groups as compared to
placebo. Warren et al., (2021) concluded in their study Bimekizumab was superior and
non-inferior to adalimumab for the primary endpoint PASI 90, 86.2% compared to
47.2%, respectively and IGA score 0/1 at 85.3% compared to 57.2% respectively.
Superiority and non-inferiority of bimekizumab versus adalimumab continued through
the secondary endpoints.
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Summary and Conclusions
Psoriasis is a complex, autoimmune disease that manifests as disease of the skin
and joints (Boehncke, 2015). The pathogenesis of psoriasis derives from dysregulation of
the adaptive and innate immune system with dendritic cells producing pro-inflammatory
cytokines in the exacerbation stage. These cytokines include Tissue Necrosis Factoralpha (TNF-a) and anti-interleukin 12, 23 and 17 (Boehncke, 2015). Successful use of
inhibitors of these cytokines further supports the belief that psoriasis is an immunemediated disease with genetic and environmental factors (Boehncke, 2015).
Manifestations of the disease include plaque, accounting for 90% of all cases, as well as
arthritic, guttate, inverse, and pustular (Boehncke, 2015). Because plaque psoriasis
accounts for most cases, it’s important to examine and synthesize the findings of
randomized controlled trials that are used to measure the severity of disease in adults with
psoriasis.
This systematic review narrowed down the search results to six randomized,
double-blinded studies that compared drug against drug or drug against placebo. These
studies were peer-reviewed and all used instruments that measured the severity of disease
in adults with psoriasis. The PASI, sPGA and BSA were used commonly for primary
endpoints (Studies 1, 3, 4, 5, & 6), however one chose the IGA for their primary endpoint
(Study 2). Most studies use the PASI (0 to 72) scale, stating that ≥12 was the threshold
for moderate disease (Studies 1, 3, 4, 5 & 6), however one chose to use a modified PASI.
The modified PASI created by Lebwohl et al., (2020) substituted anatomical areas 1-9%
as fractions rather than whole numbers; according to the authors, this allowed for more
precise measurements. Most authors used the term, “moderate” without defining
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moderate (Studies 3,4 & 5) instead of using a numeric value for sPGA. Two authors used
sPGA scores of ≥3 (Studies 1 & 6). Many authors described how the PASI and sPGA
were used to determine the severity of disease (Studies 1, 2, 3, 4 & 6). However, for the
sPGA some used a (0 to 4) scale (Study 1), some used a (0 to 6) scale (Study 3) and the
others used a (0 to 5) scale, (Studies 4, 5 & 6). Other secondary endpoints were the
Psoriasis Symptom Diary score (study 2) and the DLQI score (study 4).
All studies reported outcomes as percent achieved as compared to placebo,
comparator formulation or comparator drug (Tables B 1 – 6). Blauvelt et al., (2020)
reported achievements in PASI 90 and sPGA 0/1 as primary endpoints, and achievements
in PASI 75 & 100, sPGA 0, and DLQI 0/1 as secondary endpoints (Table B - 1). Lebwohl
et al., (2020) reported achievements in IGA 0/1 scores as primary endpoints, and
achievements in IGA 0/1 plus 2 grade improvement, IGA 0/1, PASI response, PASI 50,
75, 90 and I-NRS as secondary endpoints (Table B - 2). Papp et al., (2017) reported
achievement in PASI % improvement from baseline as the primary endpoint and
achievement in PASI 50, 90, & 100, and sPGA 0/1 as secondary endpoints (Table B – 3).
Papp et al., (2018a) reported achievements in PASI 75 as a primary endpoint and
achievements in PASI 50, 90 & 100, sPGA 0/1 and DLQI 0/1 as secondary endpoints
(Table B – 4). Papp et al., (2018b) reported achievements in PASI 90 as the primary
endpoint and achievements in PASI 75, & 100, and IGA 0/1 as secondary endpoints
(Table B – 5). Warren et al., (2021) reported achievements in PASI 90 and IGA 0/1 as
primary endpoints and PASI 75, 90 & 100 and IGA 0/1 as secondary endpoints (Table B
– 6).
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In summary, plaque psoriasis is a systemic inflammatory disease resulting from
the dysregulation of the adaptive and innate immune system, manifesting as plaque
psoriasis in 90% of all cases (Boehncke, 2015). Using a validated clinical instrument for
measuring the severity of disease informs the advanced practice nurse of the optimal
therapy and expected achievement in reduction of symptoms.
The findings of this systematic review determined that the PASI, sPGA and BSA
are the most used clinically validated instruments used for evaluating the severity of
disease in adults with psoriasis.
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Recommendations and Implications for Advanced Nursing Practice
Psoriasis is a common disorder with a prevalence in Europe and North America at
about 2%, according to the WHO and Boehncke (2015). Encountering adults with
psoriasis will not be uncommon in the acute care setting, as psoriasis places patients at
greater risk for comorbid conditions (Elmets et al., 2019). Chronic inflammatory
diseases, such as psoriasis, are known risk factors for cardiovascular disease. According
to Elmets et al. (2019), the incidence of heart disease rises in accordance with the severity
of disease. In the general population, heart disease affects 3.58/1000 person-years; in
patients with moderate psoriasis this risk increases to 4.04/1000 person-years and for
patients affected with severe psoriasis the risk escalates to 5.13/1000 person-years. The
authors found that moderate and severe psoriasis are independent risk factors for
cardiovascular events and stroke.
The link between a chronic condition such as psoriasis, increasing the risk of a
cardiovascular event presents an opportunity for advanced practice nurses in the acute
care environment. Many adults living with moderate to severe plaque psoriasis are
unaware of their risks associated with psoriasis. Being able to identify and determine the
severity of illness using validated instruments allows the advanced practice nurse to
inform and provide their patients appropriate referrals and follow-up care.
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Dissemination of Findings
This study's findings will be disseminated through the digital commons at Rhode
Island College and in a presentation to faculty and students at Rhode Island College.
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Appendix A
Table A-1
Study Specific Data
Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., Camez, A.,
Williams, D., & Langley, R. G. (2020). Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in
patients with moderate to severe plaque psoriasis: A Phase 3 randomized clinical trial. JAMA Dermatology, 156(6), 649-658.
https://doi.org/10.1001/jamadermatol.2020.0723
Aim/Purpose

Design

The research

Double -blind Multinational, 60

question is, in

placebo-

sites in Australia,

adults with

controlled

Belgium, Canada,

to severe chronic plaque

patients were randomized

moderate to severe

trial

Czech Republic,

psoriasis for more than 6

to receive risankizumab,

psoriasis, is

France, Germany,

months, with or without

150 mg or placebo at

risankizumab

Japan, South Korea

psoriatic arthritis, body surface

weeks 0 and 4. At week16

efficacious and

and the US

area >10%, PASI > or equal to

all patients received

safe as compared

Site

Sample

Method

507
Eligible patients older than 18
randomized
years old with stable moderate

Procedure

Part A was a 16-week,
double blind treatment,

12, and Static Physicians Global risankizumab 150 mg. Part

43

to placebo and

Assessment (sPGA) > or equal

B began at week 28,

continuous

to 3. PASI ranges from zero (no

patients achieving a sPGA

treatment vs.

disease) to 72 (maximal

of 0 or 1 were randomly

withdrawal

disease) an improvement

assigned 1:2 to continue

greater than or equal to 75% is

risankizumab, 150 mg or

considered clinically

placebo (withdrawal of

meaningful. sPGA ranges from

treatment) every 12

zero (clear) to 4 (severe), Parts

weeks. Patients who had

A and B were randomly

sPGA score >2

assigned using block

(inadequate response to

randomization, baseline weight,

therapy) at 28 weeks

and prior exposure to a tumor

received open label

necrosis factor alpha inhibitor.

risankizumab, 150 mg

The test drug risankizumab was

every 12 weeks. Patients

matched to look identical to the

initially randomized to

placebo.

placebo achieving sPGA
of 0 or 1 were crossed
over to receive blinded
risankizumab, 150 mg,

44

every 12 weeks (weeks
28-88). At week 32, initial
responders of treatment
who relapsed (sPGA score
equal to or >3) in part B
were retreated with open
label risankizumab 150
mg. Final follow-up at
week 104

45

Table A-2
Study Specific Data
Lebwohl, M. G., Papp, K. A., Stein Gold, L., Gooderham, M. J., Kircik, L. H., Draelos, Z. D., Kempers, S. E., Zirwas, M., Smith, K.,
Osborne, D. W., Trotman, M. L., Navale, L., Merritt, C., Berk, D. R., Welgus, H., & Investigators, A. R. Q. S. (2020). Trial of
roflumilast cream for chronic plaque psoriasis. New England Journal of Medicine, 383(3), 229-239. https://doi.org/gh5fpb
Aim/Purpose

Design

Site

Sample

Methods

Procedures

The research

Phase 2b, double-

30 sites in the US

332 subjects

Adults 18 years or

332 patients were

question is, in

blind, randomized

and Canada

older with mild,

randomized to 109

adults with

controlled trial

moderate, or severe

assigned to roflumilast

psoriasis, are

chronic psoriasis

cream 0.3%, 113

phosphodiesterase

vulgaris, affecting 2 to

assigned to roflumilast

type-4 (PDE-4)

20% of BSA, with a

cream 0.15% and 109

inhibitors an

severity of 2 or more

assigned to vehicle cream

effective treatment

on a 5-point

(placebo). Creams were

46

for psoriasis in

investigators global

applied once daily for 12

preparations of

assessment (IGA:

weeks.

0.3% or 0.15% or

assessing plaque

Primary endpoint was

vehicle cream

thickness, scaling, and

IGA status

(placebo)

erythema from zero

Secondary endpoints

(clear) to 4 (severe)

were PASI 50,75 & 90

patients were excluded

scores, Worst Itch

for areas involving the

Numeric Rating Scale

scalp, palms, and soles. (WI-NRS) zero (no itch)
Additionally, the study

10 (worst itch

was limited to 20%

imaginable), Psoriasis

with an IGA score of 2

Symptom Diary Score 16

and 15% with an IGA

item (zero to 10 scale),

score of 4. Participants

and the Dermatology

47

also were required to

Life Quality Index. The

have a modified PASI

original protocol

score of at least 2.

included a modified

Randomized in a 1:1:1

PASI.

to receive either
roflumilast 0.03%
cream, roflumilast
0.15% cream or
placebo.
Patients were excluded
for above normal
exposure to sunlight or
tanning beds, an
inability to discontinue

48

cytochrome P450
inducers or inhibitors,
and those receiving
oral roflumilast or
other PDE-4 inhibitors.

49

Table A-3
Study Specific Data
Papp, K., Bachelez, H., Costanzo, A., Foley, P., Gooderham, M., Kaur, P., Narbutt, J., Philipp, S., Spelman, L., Weglowska, J., Zhang, N., &
Strober, B. (2017). Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe
plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology,
76(6), 1093-1102. https://doi.org/10.1016/j.jaad.2016.12.014
Aim/Purpose

Design

Site

Sample

Methods

Procedures

The research

Double- blind,

Multicenter

350 subjects

Adults aged 18 to 75 with

Randomization 1:1 by

question aims to

randomized

stable moderate to severe

computer-generation, patients,

determine if

controlled

psoriasis for at least 6 months

researchers, and other

ABP501 (a

trial.

and were candidates for

personnel were blinded.

biosimilar to

systemic or phototherapy or

Patients randomized to: ABP

adalimumab) has

who were unable to tolerate at

501 with an initial loading

50

the same efficacy

least 1 conventional systemic

dose of 80 mg SQ on week 1

and safety as

therapy were eligible. Patients followed by 40 mg SQ on

adalimumab.

needed to have greater than

week 2 for 16 weeks, or:

10% of BSA affected. Patient

adalimumab (no difference in

needed a PASI score of 12 or

appearance from ABP 501)

more. Patients needed an

initial loading dose of 80 mg

sPGA score of at least

SQ on week 1 followed by

moderate severity (6-point

40mg SQ on week 2 for 16

scale). Exclusion criteria were weeks,
active TB, pregnant or having

Any patient from either arm

capacity for pregnancy, drug

with a PASI 50 from baseline

induced psoriasis, non-plaque

were eligible to continue in

variants, patients who

the study and were

previously used adalimumab,

rerandomized 1:1 to continue

51

a comparable biosimilar, or

with either ABP 50 or

any 2 or more biologics. UV

adalimumab or switch.

therapy not allowed during
trial, upper mid-strength to
low potency typical steroids
and emollients were ok within
14 days of the first study
treatment.
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Table A-4
Study Specific Data
Papp, K., Gordon, K., Thaçi, D., Akimichi, M., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., Banerjee, S., & Morita, A. (2018).
Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. New England Journal of Medicine, 379(14), 1313-1321.
https://doi.org/10.1056/NEJMoa1806382
Aim/Purpose

Design

Site

Sample

Methods

Procedures

The research

Double-blind,

82 sites in the US,

267 subjects

Adults with plaque psoriasis

Patients were randomly

question is in

randomized

Japan, Poland,

for 6 months or more with a

assigned 1:1:1: 1:1:1 to

adults with

controlled trial

Canada, Germany,

BMI between 18 to 40, who

one of 5 doses of a

psoriasis, are

Latvia, Mexico

were eligible for UV or

selective TYK2

selective inhibitors

and Australia

systemic therapy and had

inhibitor (BSM-986165:

of tyrosine kinase

moderate-severe disease

2 (TYK2) in doses

defined by a BSA of 10% or

3 mg every other day

of 3 mg daily or 3

more and a PASI score of 12

3 mg twice daily

53

mg twice daily or

or higher and a sPGA score

6 mg twice daily

6mg twice daily or

of 3 or higher (0 to 5 scale)

12 mg daily

12 mg daily or

Exclusion criteria were a

Or placebo

placebo effective

diagnosis of non-plaque

in treating

psoriasis, currently taking

The primary endpoint

psoriasis.

immunosuppressive drugs,

was PASI 75 at week 12

history of immune deficiency Secondary endpoints
or Hep B or C, or history of

were PASI 50, PASI 90

TB or risk of RB, or lack of

and PASI 100, an sPGA

response to any IL 17 or IL

score of 0 or 1 and a

23 therapy.

score of 0 or 1 on the
DLQI (0 to 30)
BSA was estimated with
the handprint method,

54

one handprint equals 1%
of BSA
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Table A-5
Study Specific Data
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018). Dual
neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1,
a 12 week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology,
79(2), 277-286 e210. https://doi.org/10.1016/j.jaad.2018.03.037
Aim/Purpose

Design

Site

Sample

Methods

Procedures

The research

Double-blinded,

6 countries

250 subjects

Adults over 18

Patients were

randomized

including Canada,

years with a

randomized in a

controlled study

Czech Republic,
diagnosis of

1:1:1:1:1:1

moderate-to-severe

computer generated

of both interleukin

plaque psoriasis for

pattern to

17 A & 17 F with

more than 6

bimekizumab

bimekizumab in

months, with a

question is in adults
with psoriasis does
dual neutralization

Hungary, Japan,
Poland, and the US

56

doses of 64 mg or

PASI equal to or

administered every

160 mg, or 160 mg

greater than 12, a

4 weeks as follows:

plus a 320 mg

BSA equal or

64 mg

loading dose, or

greater to 10%, an

160 mg

320 mg, or 480 mg

IGA equal or

160 mg+320 mg

or placebo injected

greater than 3 (0 to

loading dose

subcutaneously

5 scale) who are

320 mg

every 4 weeks

candidates for UV

480 mg

improve symptoms

and systemic

And placebo

of psoriasis

therapy.

Preparations were

Exclusion criteria

prepared off site by

include prior anti IL unblinded dedicated
17 therapy or >1
other biologic

study personnel

57

therapy, any

Treatment was

significant

administered at

neuropsychiatric

baseline, week 4

disorder, history of

and week 8.

a suicide attempt or

Efficacy and safety

suicidal ideation in

were evaluated at

the past 6 months.

weeks 1,2,4,6,8 &
12.
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Table A-6
Study Specific Data
Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P., Armstrong, A., Langley, R. G., Vanvoorden, V., De Cuyper, D., Cioffi, C.,
Peterson, L., Cross, N., & Reich, K. (2021). Bimekizumab versus adalimumab in plaque psoriasis. New England Journal of
Medicine, 385(2), 130-141. https://doi.org/10.1056/NEJMoa2102388
Aim/Purpose

Design

Site

Sample

Methods

Procedures

The research

Double-blind

Multicenter

478 subjects

Adults older than 18

Patients were randomized

question is, in

randomized trial

stratified by

with moderate-to-

in a 1:1:1 ratio by use of

adults with

of bimekizumab

region: North

severe plaque psoriasis

interactive-response

moderate to severe

as compared to

America, western

for at least 6 months,

technology to receive:

psoriasis is

adalimumab

Europe, central

PASI at least 12, IGA

bimekizumab non-

and eastern

score at least 3 (0 to 5)

bimekizumab SQ 320 mg

inferior to

Europe, or Asia

scale.

every 4 weeks for 56

adalimumab in

and Australia

weeks or:

59

treating plaque

Exclusion criteria were

psoriasis

patients previously

bimekizumab SQ 320 mg

exposed to

every 4 weeks for 16

bimekizumab or

weeks, then every 8 for

adalimumab, patients

weeks 16 to 56 or:

that had no response
within 12 weeks

Adalimumab SQ 80 mg

(primary failure) to any at baseline, followed by
anti-IL 17 biologic

40 mg 1 week later and

agent or to more than

every 2 weeks thereafter

one biologic from any

until week 24, at this

class

point switched to
bimekizumab SQ 320 mg

60

every 4 weeks to week
56
Injections were
administered
subcutaneously in the
clinic, investigators,
other personnel, and the
sponsor were blinded.
Efficacy and endpoints
evaluated by blinded
qualified medical
professionals.
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Appendix B
Table B-1
Outcome Data Collection
Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., Camez, A.,
Williams, D., & Langley, R. G. (2020). Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in
Patients with moderate to severe plaque psoriasis: A Phase 3 randomized clinical trial. JAMA Dermatology, 156(6), 649-658.
https://doi.org/10.1001/jamadermatol.2020.0723
Variables
Part A
No. of patients per

Risankizumab

Placebo

407

100

298 (73.2)

2 (2.0)

Risk difference (95% C),
%
risankizumab vs placebo

Significance

group A

PASI 90 at week
16

70.8 (65.7-76)

P <0.001 comparted
with placebo

62

sPGA 0/1 at week

340 (83.5)

7 (7.0)

76.5 (70.4-82.5)

16

PASI 75 at week

with placebo

361 (88.7)

8 (8.0)

80.6 (74.5-86.6)

16

PASI 100 at week

192 (47.2)

1 (1.0)

45.5 (40.3-50.8)

16

P <0.001 comparted
with placebo

189 (46.4)

1 (1.0)

44.8 (39.5-50)

16

DLQI 0/1 at week

P <0.001 comparted
with placebo

16

sPGA 0 at week

P <0.001 comparted

P <0.001 comparted
with placebo

266 (65.4)

3 (3.0)

62.1 (56.4-67.9)

P <0.001 comparted
with placebo

63

Variables

Part B

No. of patients per

111

225

97 (87.4)

138 (61.3)

group B

sPGA 0/1 at week

25.9 (17.3, 34.6)

52

P <0.001 comparted
with
risankizumab/placebo

sPGA 0/1 at week

90 (87.4)

16 (7.1)

73.9 (66.0, 81.9)

104

P <0.001 comparted
with
risankizumab/placebo

PASI 75 at week
52

103 (92.8)

161 (71.6)

21.2 (13.7, 28.7)

P <0.001 comparted
with

64

Risankizumab/placebo
nominal p value
PASI 90 at week

95 (85.6)

118 (52.4)

33.1 (24.0, 42.4)

52

P <0.001 comparted
with
Risankizumab/placebo
nominal p value

PASI 100 at week
52

71 (64.0)

68 (30.2)

33/7 (23.2, 44.2)

P <0.001 comparted
with
Risankizumab/placebo
nominal p value

65

Table B-2
Outcome Data Collection
Lebwohl, M. G., Papp, K. A., Stein Gold, L., Gooderham, M. J., Kircik, L. H., Draelos, Z. D., Kempers, S. E., Zirwas, M., Smith, K.,
Osborne, D. W., Trotman, M. L., Navale, L., Merritt, C., Berk, D. R., Welgus, H., & Investigators, A. R. Q. S. (2020). Trial of
roflumilast cream for chronic plaque psoriasis. New England Journal of Medicine, 383(3), 229-239.
https://doi.org/10.1056/NEJMoa2000073
Variables

Roflumilast Cream 0.3%

Roflumilast Cream 0.15%

Vehicle cream

(n=109)

(n=113)

(n=109)

28 (20 to 37)

23 (16 to 31)

8 (4 to 15)

Primary outcome
IGA score of 0 or

P = 0.001 and P – 0.004

1 plus at week 6, -

vs. vehicle group for

% of patients (95%

roflumilast 0.03% and

CI)

0.15% respectively

66

Secondary
outcomes
IGA score of 0 or

31 (23 to 41)

27 (20 to 36)

14 (8 to 15)

Although sloped in the

1 plus 2-grade

same direction, no

improvement at

definitive conclusions

wk. 12, -% of

were made due to the

patients (95% CI)

lack of a plan for
adjustment for multiple
comparisons.

IGA score of 0 or

38 (29 to 47)

32 (20 to 36)

16 (10 to 24)

94 (67 to 99)

32 (14 to 60)

24 (9 to 50)

1, at wk. 12, -% of
patients (95% CI)
IGA score of 0 or
1 plus 2-grade
improvement at

67

wk. 12 among
patients with
baseline
intertriginous-area
IGA score equal or
greater than 2, -%
of patients (95%
CI)
IGA score of 0 or
1 at wk. 12 among
patients with
baseline
intertriginous-area
IGA score equal or
greater than 2, -%

95 (69 to 99)

49 (24 to 74)

24 (9 to 50)

68

of patients (95%
CI)
Least squares

-53.2 (-61.1 to 45.2)

-55.0 (-62.8 to -47.2)

-17.0 (-25 to -9.1)

PASI 50

52 (53 to 71)

64 (55 to 73)

24 (17 to 33)

PASI 75

34 (25 to 43)

31 (23 to 40)

16 (10 to 24)

PASI 90

22 (14 to 23)

13 (8 to 21)

7 (4 to 14)

I-NRS response at

63 (51 to 73)

70 (58 to 80)

33 (22 to 45)

mean change in
PASI score at wk.
12, -% (95% CI)
PASI response at
wk. 21, -% of
patients (95% CI)

wk. 12 among
patients with

69

baseline WI-NRS
score equal to or
greater than 6, -%
of patients (95%
CI)
Least-squares
mean change in
PSD score at wk.
12, (95% CI)

-42.0 (-48.5 to -35.6)

-55.2 (-50.5 to -37.9

-20.9 (-27.3 to -14.5)

70

Table B-3
Outcome Data Collection
Papp, K., Bachelez, H., Costanzo, A., Foley, P., Gooderham, M., Kaur, P., Narbutt, J., Philipp, S., Spelman, L., Weglowska, J., Zhang, N., &
Strober, B. (2017). Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to
severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of
Dermatology, 76(6), 1093-1102. https://doi.org/10.1016/j.jaad.2016.12.014
Variables

ABP 501

Adalimumab

PASI responders

(n=175)

(n=175)

80.9

83.1

PASI %
improvement from

responders

P Value

95% CI fell between -15 to 15
margin demonstrating clinical

baseline
PASI 50 % patient

Sig Level

similarity
92.4

94.2

0.025

P=0.2973

71

PASI 75 % patient

74.4

82.7

0.025

P=0.0884

47.1

47.4

0.025

P=0.0916

16.9

19.7

0.025

P=0.6736

ABP 501

Adalimumab

Treatment difference

P Value

101/172 (58.7)

113/173 (65.3)

-7.4

0.1422

-18.0 (13.57)

-22.1 (17.11)

1.93

0.0809

responders

PASI 90 % patient
responders

PASI 100 %
patient responders

Variables
SPGA
sPGA, clear/almost
clear, n/total n (%)

72

Change from
baseline, mean
(SD)

73

Table B-4
Outcome Data Collection
Papp, K., Gordon, K., Thaçi, D., Akimichi, M., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., Banerjee, S., & Morita, A. (2018).
Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. New England Journal of Medicine,
379(14), 1313-1321. https://doi.org/10.1056/NEJMoa1806382
Variables
BMS-986165

3 mg daily
(n=44)

(n=45)

3 mg every
other day
(n=44

3 (7)

4 (9)

17 (39)

Placebo

3 mg twice
daily
(n=45)

6mg twice daily
(n=45)

12 mg daily
(n=44)

PASI 75 primary
endpoint

No. of patients (%)

31 (69)

30 (67)

33 (75)

<0.001

<0.001

<0.001

<0.001

30 (68)

41 (91)

35 (78)

39 (89)

P value vs. placebo
0.49
PASI 50
No. of patients (%)

14 (31)

19 (43)

74

Difference vs.
placebopercentage points
(95& CI)

12 (-8 to 32)

37 (18 to 56)

60 (41 to 75)

47 (29 to 65)

58 (41 to 75)

PASI 90
No. of patients (%)

1 (2)

7 (16)

20 (44)

14 (-7 to 33)

42 (21 to 60)

20 (44)

19 (43)

3 (7)

Difference vs.
placebo-

5 (-16 to 25)

47 (29 to 65)
41 (20 to 58)

percentage points

-

(95& CI)
PASI 100

0

1 (2)

0

4 (9)

8 (18)

11 (25)

No. of patients (%)
-

Difference vs.
placebopercentage points
(95& CI)

-

2 (-18 to 23)

9 (-13 to 30)

18 (-4 to 38)

25 (4 to 44)

75

sPGA score 0

3 (7)

9 (20)

17 (39)

34 (76)

29 (64)

14 (-7 to 33)

32 (11 to 50)

69 (51 to 83)

58 (38 to 74)

7 (16)

7 (16)

19 (42)

27 (60)

33 (75)

orm1
No. of patients (%)
Difference vs.

-

placebo-

68 (50 to 82)

percentage points
(95% CI)
DLQI score 0 or 1

2 (4)

28 (64)

No. of patient (%)
Difference vs.
placebopercentage points
(95% CI)

12 (-2 to 26)

12 (-2 to 26)

38 (20 to 54)

56 (38 to 71)

59 941 to 74)
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Table B-5
Outcome Data Collection
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018). Dual
neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE
ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of
Dermatology, 79(2), 277-286 e210. https://doi.org/10.1016/j.jaad.2018.03.037
Variables

Placebo

BZK 64 mg

BZK 160 mg

BZK 160 mg
plus 320 mg
loading dose

BZK 320 mg

BZK 480 mg

Significance

PASI 75 response
% patients wk. 12

4.8

61.5 %

81.4%

85 %

93.0 %

83.7 %

P <0.001

PASI 90 response
% patients wk. 12

0

46.2 %

67.4 %

75.0 %

79.1 %

72.1 %

P <0.001

PASI 100 response
% patients wk.12

0

28.2 %

27.0 %

60.0 %

55.8 %

48.8 %

P <0.001
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IGA 0/1response
% patients wk.12

4.8

51.3 %

74.4 %

75.0 %

86.0 %

76.6 %

P <0.001
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Table B-6
Outcome Data Collection
Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P., Armstrong, A., Langley, R. G., Vanvoorden, V., De Cuyper, D.,
Cioffi, C., Peterson, L., Cross, N., & Reich, K. (2021). Bimekizumab versus adalimumab in plaque psoriasis. New England
Journal of Medicine, 385(2), 130-141. https://doi.org/10.1056/NEJMoa2102388
Variables

Primary end
points
PASI 90 response
at wk. 16
IGA score of 0/1 at
wk. 16

Hypothesis Test
in Statistical
Hierarchy

Total
Bimekizumab
(n=319)

Adalimumab
(n=159)

No. (%)

no. (%)

H1 and H3

275 (86.2)

75 (47.2)

H2 and H4

272 (85.3)

91 (57.2)

Adjusted Risk
Difference:
Total
bimekizumab
vs. adalimumab
(95% CI)
Percentage
points

Bimekizumab
Every 4 WK
(n=158)

Adjusted Risk
difference:
bimekizumab
Every 4 WK
vs. adalimumab
(95% CI)

39.3
(30.9-47.7)

NA

NA

28.2
(19.7-36.7)

NA

NA

(95% CI)
p<0.001noninferior and
superiority
(95% CI)
p<0.001non-
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inferior and
superiority
(95% CI)
p<0.001noninferior and
superiority

Secondary end
points

PASI 100 response
at wk. 16

H5

194 (60.8)

38 (23.9)

37.0
(28.6-45.3)

NA

NA

(95% CI)
p<0.001noninferior and
superiority

PASI 75 response
at wk. 4

H6

244 (76.5)

50 (31.4)

44.8
(36.3-54.4)

NA

NA

(95% CI)
p<0.001noninferior and
superiority

PASI 100 response
at wk. 24

H7 and H10

213 (66.8)

47 (29.6)

37.1
(28.5-45.7)

107 (67.7)

37.9
(28.1-47.7)

(95% CI)
p<0.001noninferior and
superiority

PASI 90 response
at wk. 24

H8 and H11

273 (85.6)

82 (51.6)

33.9
(25.4-42.4)

136 (86.1)

34.3
(25.2-43.5)

(95% CI)
p<0.001noninferior and
superiority

IGA score 0/1 at
wk. 24

H9 and H12

276 (86.5)

92 (57.9)

28.7
(20.2-37.1)

136 (86.1)

28.3
(19.1-37.5)

(95% CI)
p<0.001non-
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inferior and
superiority
H1 & H2 tested
non-inferiority of
bimekizumab as
comparted to
adalimumab

H3 & H4 tested H7 & H8 & H9
the superiority
tested the
of bimekizumab superiority of
compared to
bimekizumab
adalimumab for as compared to
PASI 90
adalimumab for
PASI 100

H10 & H11 &
H12 evaluated
the same
endpoints on
the basis of the
group receiving
bimekizumab
every 4 weeks

81

Appendix C
Table C-1
Critical Appraisal Skills Progamme
Study 1: Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., Camez,
A., Williams, D., & Langley, R. G. (2020). Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in
patients with moderate to severe plaque psoriasis: A Phase 3 randomized clinical trial. JAMA Dermatology, 156(6), 649-658.
https://doi.org/10.1001/jamadermatol.2020.0723
A. Are the results of the trial valid?

Yes

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?

X

Can’t tell

No
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4. Were patients, health workers, and study personnel “blind”
to treatment?

X

5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the groups
treated equally?
B. What are the results?
7. How large was the treatment effect?

X the
study was
randomized 4:1
X

Yes
Part A (73.2%)
treatment arm vs
(2.0%) placebo
achieved PASI
90 Part B
treatment arm
intention to treat
analysis (74% &
83.8%) achieved
PASAI 90 and
sPGA 0/1 at
week 16 vs
placebo at (2%
& 6.1%)

Can’t tell

No

83

8. How precise was the estimate of the treatment effect?

C. Will the results help locally?

P <0.001

Yes

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes considered?

X

11. Are the benefits worth the harms and costs?

X

Can’t tell

No

84

Table C-2
Critical Appraisal Skills Progamme
Study 2: Lebwohl, M. G., Papp, K. A., Stein Gold, L., Gooderham, M. J., Kircik, L. H., Draelos, Z. D., Kempers, S. E., Zirwas, M., Smith,
K., Osborne, D. W., Trotman, M. L., Navale, L., Merritt, C., Berk, D. R., Welgus, H., & Investigators, A. R. Q. S. (2020). Trial of
roflumilast cream for chronic plaque psoriasis. New England Journal of Medicine, 383(3), 229-239.
https://doi.org/10.1056/NEJMoa2000073
A. Are the results of the trial valid?
1. Did the trial address a clearly focused issue?

Yes
x

2. Was the assignment of patients to treatments randomized?

x

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?

x

4. Were patients, health workers, and study personnel “blind” to
treatment?

x

5. Were the groups similar at the start of the trial?

x

Can’t tell

No
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6. Aside from the experimental intervention, were the groups
treated equally?
B. What are the results?

x

Yes

7. How large was the treatment effect?

28% of the
roflumilast 0.3%
group showed an
improvement,
23% of the
roflumilast
0.15% group
showed an
improvement
and 8% of the
vehicle cream
group showed an
improvement.

8. How precise was the estimate of the treatment effect?

P = 0.001 in the
0.3%
Roflumilast
group
P= 0.004 in the
0.15%
Roflumilast
group

Can’t tell

No
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C. Will the results help locally?

Yes

Can’t tell

9. Can the results be applied in your context?
10. Were all clinically important outcomes considered?

x
x

11. Are the benefits worth the harms and costs?

x

No

87

Table C-3
Critical Appraisal Skills Progamme
Study 3: Papp, K., Bachelez, H., Costanzo, A., Foley, P., Gooderham, M., Kaur, P., Narbutt, J., Philipp, S., Spelman, L., Weglowska, J.,
Zhang, N., & Strober, B. (2017). Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate
to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of
Dermatology, 76(6), 1093-1102. https://doi.org/10.1016/j.jaad.2016.12.014
A. Are the results of the trial valid?

Yes

Can’t tell

1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments
randomized?

x

3. Were all of the patients who entered the trial
properly accounted for at its conclusion?

x

4. Were patients, health workers, and study personnel
“blind” to treatment?

x

No
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5. Were the groups similar at the start of the trial?

x

6. Aside from the experimental intervention, were the
groups treated equally?

x

B. What are the results?
7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the results help locally?

Yes

Can’t tell

No

Can’t tell

No

The percent improvement
from baseline at week 16
was 83.06% for
Adalimumab and 80.91%
for ABP 501
95% CI

Yes

9. Can the results be applied in your context?

x

10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x
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Table C-4
Critical Appraisal Skills Progamme
Study 4: Papp, K., Gordon, K., Thaçi, D., Akimichi, M., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., Banerjee, S., & Morita, A.
(2018). Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. New England Journal of Medicine, 379(14), 1313-1321.
https://doi.org/10.1056/NEJMoa1806382
A. Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the
groups treated equally?
B. What are the results?

Yes

Can’t tell

No

Can’t tell

No

x
x
x
x
x
x

Yes
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7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the results help locally?
9. Can the results be applied in your context?
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harms and costs?

The largest dose of BMS986165, 12mg daily showed
a PASI 75 improvement in
75 % of patients.
P value <0.001 vs placebo
Yes

Can’t tell
x
x
x

No

91

Table C-5
Critical Appraisal Skills Progamme
Study 5: Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018). Dual
neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE
1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of
Dermatology, 79(2), 277-286 e210. https://doi.org/10.1016/j.jaad.2018.03.037
A. Are the results of the trial valid?

Yes

Can’t tell

1. Did the trial address a clearly focused issue?

x

2. Was the assignment of patients to treatments
randomized?

x

3. Were all of the patients who entered the trial properly
accounted for at its conclusion?

x

4. Were patients, health workers, and study personnel
“blind” to treatment?

x

5. Were the groups similar at the start of the trial?

x

No
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6. Aside from the experimental intervention, were the
groups treated equally?

x

B. What are the results?

Yes

7. How large was the treatment effect?

There was significant
(p=<0.001) PASI 75, 90,
100 and IGA improvement
in all bimekizumab groups
as compared to placebo.

8. How precise was the estimate of the treatment effect?

P <0.001

C. Will the results help locally?

Yes

9. Can the results be applied in your context?

x

10. Were all clinically important outcomes considered?

x

11. Are the benefits worth the harms and costs?

x

Can’t tell

No

Can’t tell

No

93

Table C-6
Critical Appraisal Skills Progamme
Study 6: Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P., Armstrong, A., Langley, R. G., Vanvoorden, V., De
Cuyper, D., Cioffi, C., Peterson, L., Cross, N., & Reich, K. (2021). Bimekizumab versus adalimumab in plaque psoriasis. New
England Journal of Medicine, 385(2), 130-141. https://doi.org/10.1056/NEJMoa2102388
A. Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments randomized?
3. Were all of the patients who entered the trial properly
accounted for at its conclusion?
4. Were patients, health workers, and study personnel “blind”
to treatment?
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the groups
treated equally?
B. What are the results?
7. How large was the treatment effect?

Yes

Can’t tell

No

x
x
x
x
x
x
Yes
Bimekizumab was
superior and non-inferior
to adalimumab for the

Can’t tell

No

94

primary endpoint PASI
90, 86.2% comparted to
47.2%, respectively and
IGA score 0/1 at 85.3%
comparted to 57.2%
respectively. Superiority
and non-inferiority of
Bimekizumab vs
adalimumab continued
through the secondary
endpoints.
8. How precise was the estimate of the treatment effect?
C. Will the results help locally?
9. Can the results be applied in your context?
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harms and costs?

(95% CI) p<0.001
Yes

Can’t tell
x
x
x

No

95

Appendix D
Cross-Study Analysis
Author/Year

Comparisons or
Protocol of Study

Primary and Secondary
Endpoints

Validated Instruments Used for
Evaluating the Severity of Psoriasis

Outcome/Results

Study 1
Blauvelt et
al., (2020)

Is risankizumab
efficacious and safe as
compared to placebo
and continuous
treatment vs.
withdrawal

Primary end points were
PASI 90 and sPGA 0/1
improvement at week 16
Secondary end points
were PASI 75, PASI
100, sPGA 0, and DLQI
0/1 at week 16

PASI ≥ 12 (0 to 72) scale
sPGA ≥ 3 (0 to 4) scale
BSA ≥ 10%
The authors note that a PASI 75 (or
75% improvement in symptoms) is
consider clinically significant. They
describe the PASI ranging from 0
(no disease) to 72 (maximal
disease) and sPGA ranging from 0
(clear) to 4 (severe)

Part A (73.2%) treatment arm vs
(2.0%) placebo achieved PASI 90
Part B treatment arm intention to
treat analysis (74% & 83.8%)
achieved PASAI 90 and sPGA 0/1
at week 16 vs placebo at (2% &
6.1%)

Study 2
Lebwohl et
al., (2020)

Are phosphodiesterase
type-4 (PDE-4)
inhibitors an effective
treatment for psoriasis
in preparations of
0.3% or 0.15% or
vehicle cream
(placebo)

Primary outcome of IGA
0/1 at week 6. Secondary
outcomes are IGA 0/1
plus 2-grade
improvement at week
12, IGA score 0/1 at
week 12, IGA score of
0/1 plus 2-grade among
patients with baseline
intertriginous-area IGA
score equal to or >2,

IGA ≥ 2 (0 to 5) scale
Modified PASI ≥ 2 (0 to 72) scale
WI-NRS (0 to 10) scale
Psoriasis Symptom Diary score (16
item scale) each item (0 to 10) scale
The authors note the IGA score
ranges from 0 (clear), 1 (almost
clear) to 4 (severe) and the modified
PASI ranging from 0 (no disease) to
72 (maximal disease)

28% of the roflumilast 0.3% group
showed an improvement, 23% of
the roflumilast 0.15% group
showed an improvement and 8% of
the vehicle cream group showed an
improvement.
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Study 3
Papp et al.,
(2017)

aims to determine if
ABP 501 (a biosimilar
to adalimumab) has
the same efficacy and
safety as adalimumab

IGA /01 among patients
with baseline
intertriginous-area IGA
score equal to or >2,
PASI response at 12
weeks for PASI 50, 75
and 90 and WI-NRS
response at 12 weeks
among patients with
baseline WI_NRS score
equal or >6. Secondary
outcomes are reported as
point estimates without p
values, no clinical
inferences can be made.

The authors describe the modified
PASI as a tool they developed for
measuring, with precision, limited
disease. Anatomical areas 1 to 9%
are recorded as a fraction rather
than a whole number, allowing for
derivation from all elements of the
PASI score.

Primary efficacy end
point was the percent
improvement in PASI
from baseline to week
16. PASI 50 and PASI
75 responses, sPGA /01.
Secondary end points
were safety and was
assessed monitoring for
treatment-emergent
adverse events (TEAEs)
and serious adverse
vents (SAEs), laboratory
data, vital sings and
immunogenicity.

PASI ≥ 12 (0 to 72) scale
sPGA “moderate” (0 to 6) scale
BSA ≥10%
The authors describe the PASI as
“higher scores indicating more
severe disease” and sPGA as
“ranging from clear to very severe”.

The percent improvement from
baseline at week 16 was 83.06% for
adalimumab and 80.91% for ABP
501
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Study 4
Papp et al.,
(2018a)

are selective inhibitors
of tyrosine Kinase 2
(TYK2) in doses of
3mg daily or 3mg
twice daily or 6mg
twice daily or 12mg
daily or placebo
effective in treating
psoriasis

Primary end point was a
75% or better reduction
in the baseline PASI
score at week 12.
Secondary end points
were PASI 50, PASI 90,
PASI 100 sPGA 0/1 and
DLQI at 12 weeks

PASI ≥ 12 (0 to 72) scale
The largest dose of BMS-986165,
sPGA “moderate” (0 to 5) scale
12mg daily showed a PASI 75
BSA ≥ 10%
improvement in 75 % of patients.
The authors report that the patient’s
handprint represents 1% of body
surface area
They describe the PASI as a
summed score of redness, thickness,
and scaliness of psoriatic skin
lesions, involving the arms, legs,
trunk and head, ranging from 0 to
72 with higher scores indication
severe disease.
They describe the sPGA ranges
from 0 (clear) to 5 (very severe
disease)

Study 5
Papp et al.,
(2018b)

does dual
neutralization of both
interleukin 17 A & 17
F with bimekizumab
in doses of 64mg or
160mg, or 160mg plus
a 320mg loading dose,
or 320mg, or 480mg
or placebo injected
subcutaneously every
4 weeks improve
symptoms of psoriasis

Primary efficacy end
point was the PASI 90 at
week 12.
Secondary end points
were PASI 90 at week 8,
PASI 75 and PASI100 at
week 12 and IGA with
equal or >2 categories of
improvement from
baseline at weeks 8 and
12.

PASI ≥ 12 (0 to 72) scale
sPGA “moderate” (0 to 5) scale
BSA ≥ 10%
The authors make no reference
describing the clinically validated
instruments however, they do
define abbreviations used:
PASI 75: ≥75% reduction in
baseline Psoriasis Area and Severity
Index
PASI 90: ≥90% reduction in baseline Psoriasis Area and Severity
Index

There was significant (p=<0.001)
PASI 75, 90, 100 and IGA
improvement in all bimekizumab
groups as compared to placebo.
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PASI100: ≥100% reduction in
baseline Psoriasis Area and Severity
Index
Study 6
Warren et al.,
(2021)

in adults with
moderate to severe
psoriasis is
bimekizumab noninferior to
adalimumab in
treating plaque
psoriasis

Primary end points were
PASI 90 at week 16 and
IGA 0/1 with a 2-grade
improvement from
baseline at week 16.
Secondary end points
were PASI 100 at week
16, PASI 75 at week 4,
PASI 100 at week 24
and IGA 0/1 at week 24.
Exploratory end points
were DLQI score 0/1at
week 25 with PASI 90
and PASI 100 and DLQI
score 0/1 at week 56 for
patients switched from
adalimumab to
bimekizumab and did
not have a PASI 90 or
DLQI 0/1 score at week
24

PASI ≥ 12 (0 to 72) scale
IGA ≥ 3 (0 to 5) scale
BSA ≥10%
The authors state the PASI score
ranges from 0 to 72 with higher
numbers indicating severe disease
They state the IGA ranges from 0
(clear) to 4 (severe disease)

Bimekizumab was superior and
non-inferior to adalimumab for the
primary endpoint PASI 90, 86.2%
comparted to 47.2%, respectively
and IGA score 0/1 at 85.3%
comparted to 57.2% respectively.
Superiority and non-inferiority of
bimekizumab vs adalimumab
continued through the secondary
endpoints.

